Therapeutic Strategies against Neurodegenerative Conditions (TSANC)

Venue: The Boston Marriott

Location: Burlington, Massachusetts, United States

Event Date/Time: Oct 10, 2005 End Date/Time: Oct 10, 2005
Early Registration Date: Sep 10, 2005
Abstract Submission Date: Sep 10, 2006
Report as Spam

Description

Neurodegenerative diseases such as Alzheimer's and Parkinson's disease and conditions such as stroke disrupt the quality of life for patients, extracts an enormous emotional and physical strain on caregivers, and cost society billions of dollars annually. Increasing numbers of elderly people in the population has resulted in a sharp increase in the prevalence of these neurological conditions. Underlying a majority of these disorders is the abnormal degeneration of neurons. In most instances, the etiological causes are unknown and they have a progressive development. While symptomatic treatments are available for many neurodegenerative disorders, drugs to reduce or prevent the neuronal loss in patients have yet to be identified. Intense research over the past few years has generated a rich and complex body of information about the mechanisms and pathophysiology of neurodegenerative conditions. This knowledge has provided the opportunity to find novel targets for drug development and resulting in the initiation of several promising clinical trials.

The conference focuses on the latest and most exciting research findings in the identification of novel molecular targets and the development of potential therapeutic strategies for neurodegenerative conditions. We have an excellent list of speakers from academia, industry and government whose presentations will cover a range of topics within the area of neurodegeneration and therapy and with information from cell culture models to clinical trials.

The conference will take place in Boston on Monday, October 10 and Tuesday, October 11. Please bring this conference to the attention of your colleagues, post-doctoral fellows and students who may benefit from attending the meeting. Please register early and submit an abstract. Come to Boston earlier or stay later and enjoy the many historic and cultural delights of this beautiful city.

It will be my pleasure to welcome you to the first annual conference on Therapeutic Strategies against Neurodegenerative Conditions in Boston.

Sincerely,

Santosh R. D'Mello, Ph.D.
Conference Chairperson

Venue

Additional Information

AGENDA

DAY 1 - Monday, October 10, 2005

 
7:15 Registration and Breakfast
   
8:15 Opening Remarks
   
8:30 Neuroprotective Approaches to Alzheimer's Disease
  John Davis,
  GlaxoSmithKline
   
9:00 Amyloid-based Therapeutic Strategies for Alzheimer's Disease
  Rusell Rydel, Ph.D., Vice President, Pharmacology
  Elan Pharmaceuticals
   
9:30 Drug Development Targets and Strategies for Neuroprotection and Neurorestoration in Alzheimer's Disease
  Martin Tolar, M.D., Ph.D, Director, Clinical Strategic Partnerships
  Pfizer Global Research
   
10:00 APOE4 and Alzheimer's Disease: From Susceptibility Gene Variant to Clinical Trial to New Drug Discovery
  Ann Saunders, Ph.D., Therapy Area Team Leader, Metabolic & Viral Diseases
  GlaxoSmithKline
   
10:30 Refreshment Break and Exhibiting
   
11:00 KEYNOTE SPEAKER
  Steve M. Paul, Executive Vice President, Lilly Research Labs
  Eli Lilly & Co.
   
12:00 Lunch
   
1:00 Parkinson's Disease:  Mechanisms and Models
  Serge Przedborski, M.D., Ph.D., Professor, Center for Neurology and Behavior
  Columbia University College of Physicians and Surgeons
   
1:30 The Therapeutic Potential of Metabotropic Glutamate Receptor Ligands in the Treatment of Neurodegenerative Disease
  Michael Marino, Ph.D., Neuroscience Drug Discovery, Movement Disorders
  Merck Research Labs
   
2:00 The Role of Iron and Glutathione in Parkinson's Disease:  Toward Rational Therapeutics
  Julie Andersen, Ph.D., Professor
  Bucks Institute for Age Research
   
2:30 Neuroprotection and Neurorepair:  Small Molecule Approaches for Parkinson's Disease
  Michael J. O'Neill, Principal Research Scientist/Team and Project Leader, Neurodegeneration Group,
  Eli Lilly (UK)
   
3:00 Refreshment Break and Exhibiting
   
3:30 Therapeutic Strategies for the Disease Modification of Alzheimer's Disease
  J. Steven Jacobsen, Ph.D., Associate Director, Neuroscience
  Wyeth Research
   
4:00 TBA
  Mark A. Findeis, Ph.D., Vice President of Research
  Satori Pharmaceuticals, Inc.
   
4:30 TBA
  David A. Lowe, Chief Scientific Officer
  Memory Pharmaceuticals Corporation
   
5:30 Networking Reception
 
DAY 2 - Tuesday, October 11, 2005
   
7:15 Registration and Breakfast
   
8:15 Recap of Day 2
   
8:30 Signal Transduction
  Zewei Huang, Ph.D., Professor
  The Burnham Institute
   
9:00 A Delicate Balance: Neuronal Life and Death
  Carol Troy, M.D., Ph.D, Associate Professor of Clinical Pathology and Neurology
  Taub Center for the Study of Alzheimer's Disease and the Aging Brain
  Columbia University College of Physicians and Surgeons
   
9:30 Regulatory Pathways that Control Repair and Regeneration
  Lee Rubin, Ph.D., Executive Vice President of Research and Chief Scientific Officer
  Curis, Inc.
   
10:00 The Transcription Factors Activated by Oxidative Stress that May Mediate Protective or Deleterious Responses
  Rajiv Ratan, M.D., Ph.D, Neurology
  Beth Israel Deaconess Medical Center, Harvard Medical School
   
10:30 Refreshment Break and Exhibiting
   
11:00 KEYNOTE SPEAKER
  Kevin A. Roth, M.D., Ph.D., Director, Neuropathology
  University of Alabama at Birmingham
   
12:00 Lunch
   
1:00 Neurodegeneration Approved Drug Screening and Therapeutics Development
  Jill Heemskerk, Ph.D., Program Director, Technology Development
  National Institute of Neurological Disorders and Stroke, NIH
   
1:30 Neuroprotection by 3' Substituted Indolones
  Santosh R. D'Mello, Ph.D., Professor, Dept of Molecular & Cell Biology
  University of Texas at Dallas
   
2:00 Therapeutic Potential fo Supressing CPK's
  David Park, M.D.
  University of Ottowa
   
2:30 Potential Use of Mood Stabilizing Drugs for Neurodegenerative Diseases
  De-Maw Chuang, Ph.D., Chief, Section on Molecular Neurobiology
  National Institute of Mental Health, National Institutes of Health
   
3:00 Refreshment Break and Exhibiting
   
3:30 TBA
  James Wang
  En Vivo
   
4:00 TBA
  Barbara Slusher, Ph.D., Senior Vice President, Research
  Guilford Pharmaceuticals
   
4:30 Oral Presentations of Selected Abstracts
  To Be Announced on the GTCbio Website
   
5:00 Conference Concludes
*****On October 11th there will be concurrent sessions on the business and licensing aspects of emerging therapeutics.

Types